Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07665723 · ClinicalTrials.gov registry record · Phase 1
An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT07665723 is a Phase 1 study that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 25 participants.
The verdict
NCT07665723, a Phase 1 study, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the disease-drug-drug interaction (DDDI) potential of afimkibart (also known as RO7790121). This will be assessed by the characterization of the pharmacokinetics (PK) of cytochrome P450 (CYP) enzyme substrates alone and after administration of afimkibart in participants with moderately to severely active ulcerative colitis (UC).
Interventions
- DRUG Afimkibart
- DRUG Omeprazole
- DRUG Caffeine
- DRUG Warfarin
- DRUG Dextromethorphan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2026-06-30 |
| Est. Completion | 2030-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07665723
The ClinicalTrials.gov registry entry for NCT07665723 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Afimkibart is the first listed.
NCT07665723 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07665723 about?
NCT07665723 is a clinical study titled "An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis". The purpose of this study is to evaluate the disease-drug-drug interaction (DDDI) potential of afimkibart (also known as RO7790121). This will be assessed by the characterization of the pharmacokinetics (PK) of cytochrome P450 (CYP) enzyme substrates alone and after administration of afimkibart in p...
What is the current status of trial NCT07665723?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2026-06-30. Estimated completion is 2030-12-31.
What interventions are being tested in trial NCT07665723?
The interventions under investigation include: Afimkibart (DRUG), Omeprazole (DRUG), Caffeine (DRUG), Warfarin (DRUG), Dextromethorphan (DRUG).
Who is sponsoring clinical trial NCT07665723?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.